ERBB2 and neoplasm: An increasing body of evidence is emerging that Th1/CTL-driven anti-tumor immunity plays a critical role in contributing to enhanced patient outcome and therapeutic responsiveness in breast cancer patients, particularly within the poor outcome HER2 and basal subtypes.